Home/Filings/4/0001415889-24-014007
4//SEC Filing

Feener Edward P. 4

Accession 0001415889-24-014007

CIK 0001348911other

Filed

May 20, 8:00 PM ET

Accepted

May 21, 5:59 PM ET

Size

17.7 KB

Accession

0001415889-24-014007

Insider Transaction Report

Form 4
Period: 2024-05-17
Feener Edward P.
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2024-05-17+18,78980,946 total
  • Exercise/Conversion

    Restricted Stock Unit

    2024-05-172,43114,583 total
    Common Stock (2,431 underlying)
  • Exercise/Conversion

    Performance Stock Units

    2024-05-177,29214,583 total
    Common Stock (7,292 underlying)
  • Sale

    Common Stock

    2024-05-20$11.76/sh8,088$95,15172,858 total
  • Exercise/Conversion

    Restricted Stock Unit

    2024-05-171,77414,190 total
    Common Stock (1,774 underlying)
  • Exercise/Conversion

    Performance Stock Units

    2024-05-177,2920 total
    Common Stock (7,292 underlying)
Footnotes (7)
  • [F1]Each restricted stock unit ("RSU") and performance stock unit ("PSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
  • [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
  • [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.7644 to $11.965 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 17, 2022, subject to continued service through each vesting date.
  • [F5]1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, subject to continued service through each vesting date.
  • [F6]Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on June 8, 2023. Each PSU represents a contingent right to receive one share of Issuer Common Stock upon the Issuer's achievement of performance metric goals ("Performance Metrics"). 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of August 17, 2023, upon Performance Metrics achieved, subject to continued service through each vesting date.
  • [F7]Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on January 10, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Metrics. 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of February 17, 2024, upon Performance Metrics achieved, subject to continued service through each vesting date.

Issuer

KalVista Pharmaceuticals, Inc.

CIK 0001348911

Entity typeother

Related Parties

1
  • filerCIK 0001691090

Filing Metadata

Form type
4
Filed
May 20, 8:00 PM ET
Accepted
May 21, 5:59 PM ET
Size
17.7 KB